Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 6,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Head and Neck Cancer
Interventions: Everolimus, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 89 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Chicago, Illinois • Evanston, Illinois

Conditions: Multiple Myeloma, Plasma Cell Disorder
Interventions: HDP-101; Drug
Lead sponsor: Heidelberg Pharma AG; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 5
States / cities: Atlanta, Georgia • Louisville, Kentucky • Omaha, Nebraska + 2 more

Conditions: Cystic Fibrosis
Interventions: VX-828, Placebo, Itraconazole, Midazolam, Tezacaftor, VX-118, Deutivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 12
States / cities: Hollywood, Florida • Orlando, Florida • Overland Park, Kansas + 9 more

Conditions: Healthy
Interventions: [14C]-LY3866288, LY3866288; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: Iberdomide; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Acne Vulgaris
Interventions: Area cleaned with saline water and occluded with Tegaderm, Area cleaned with saline water, Area cleaned with Ethyl alcohol solution, Visonac left on the skin for 24 hours in facial area one, Visonac wiped off after one hour, Visonac left on the skin 24 hours in facial area two; Drug
Lead sponsor: Photocure; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Overactive Bladder
Interventions: (VERV™ System), Sham version of (VERV™ System); Device
Lead sponsor: Ethicon Endo-Surgery; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 14
States / cities: Tucson, Arizona • Murrieta, California • Washington D.C., District of Columbia + 11 more

Conditions: Breast Cancer
Interventions: Enzalutamide, exemestane, Placebo (for enzalutamide); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 89
States / cities: Aurora, Colorado • Colorado Springs, Colorado • Lakewood, Colorado + 54 more

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: Aprepitant 125 mg, Fosaprepitant 115 MG, Dexamethasone, Ondansetron 16 MG; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: The Bronx, New York

Conditions: Pancreatic Adenocarcinoma, Metastatic
Interventions: Nab-paclitaxel, Gemcitabine, VCN-01; Drug · Genetic
Lead sponsor: Theriva Biologics SL; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Newport Beach, California • Sacramento, California • Louisville, Kentucky + 4 more

Conditions: Hepatitis C
Interventions: TMC435, Placebo, Peg-IFN-alfa-2a (P), Ribavirin (R); Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 17
States / cities: La Jolla, California • Los Angeles, California • Jacksonville, Florida + 14 more

Conditions: Healthy
Interventions: GSK2336805 30 mg, GSK2336805 60 mg, GSK2336805 120 mg, TMC435 150 mg (Treatment A), GSK2336805 60 mg (Treatment B and part of Treatment C and D), TMC435 100 mg (part of Treatment C), TMC435 150 mg (part of treatment D); Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cypress, California

Conditions: Patellofemoral Pain Syndrome, Knee Pain Chronic, Patellofemoral Syndrome, Anterior Knee Pain Syndrome
Interventions: Psychologically Informed Education, Biomedical Education (Control); Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 12 Years to 18 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Alzheimer Disease, Healthy Volunteers
Interventions: TAK-071, Donepezil, TAK-071 Placebo, Donepezil Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 179 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Pregnancy
Interventions: Investigational MRI coil designed for pregnant women, MRI Scan; Device · Procedure
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glioma
Interventions: Rhenium Liposome Treatment; Drug
Lead sponsor: Cerenome; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 4
States / cities: Manhasset, New York • Columbus, Ohio • Dallas, Texas + 1 more

Conditions: Healthy Volunteers
Interventions: KarXT, Midazolam, Fexofenadine, Digoxin; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy
Interventions: MBX 2109 (Part A), MBX 2109 (Part B), Placebo; Drug
Lead sponsor: MBX Biosciences; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: Renal Dialysis, Kidney Failure, Chronic
Interventions: MK-2060, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Orlando, Florida • Saint Paul, Minnesota • Knoxville, Tennessee

Conditions: Achilles Tendinopathy
Interventions: Physical Therapy, Shockwave Therapy, Photobiomodulation Therapy; Other · Device
Lead sponsor: Musculoskeletal Injury Rehabilitation Research for Operational Readiness; Federal
Eligibility: 18 Years to 64 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Glioma
Interventions: [11C]Acetate Brain Imaging; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer
Interventions: ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin; Drug
Lead sponsor: Enliven Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Plantation, Florida • St Louis, Missouri • Fairfax, Virginia

Conditions: Rheumatoid Arthritis
Interventions: SAIT101, MabThera, Rituxan; Biological
Lead sponsor: Archigen Biotech Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Anniston, Alabama • El Cajon, California • La Mesa, California + 10 more

Conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm
Interventions: Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, Vorinostat; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2027
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 14 more

Search by objective public record fields.

Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

A Study of [14C]-LY3866288 in Healthy Participants

A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants

Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients

Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Low Dose Aprepitant for Patients Receiving Carboplatin

Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.

Maladaptive Psychosocial Beliefs and Adolescents With Patellofemoral Pain

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

Advanced Fetal Imaging - Phase II

Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects

Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)

Shockwave, Photobiomodulation, and Physical Therapy for Achilles Tendinopathy

[11C]Acetate PET in Patients With Glioma

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas